Vaccine Evaluation Methods and Studies

A special issue of Vaccines (ISSN 2076-393X).

Deadline for manuscript submissions: closed (31 March 2021) | Viewed by 26809

Special Issue Editors

Radiation Vaccine Team, Korea Atomic Energy Research Institute, Daejeon, Korea
Interests: vaccines; pneumococcus; group B streptococci; influenza; infectious disease; opsonophagocytosis assay; bacterial pathogenesis
School of Medicine, Korea University Guro Hospital, Seoul 08308, Korea
Interests: vaccines; pneumococcus; group B streptococci; influenza; infectious disease; opsonophagocytosis assay; bacterial pathogenesis

Special Issue Information

Dear Colleagues,

The goal of the Special Issue “Vaccine Evaluation Methods and Studies” is to present technological and conceptual advances in fundamental vaccine development.

This Special Issue invites contributions in the areas of vaccine development and testing against well-known, as well as emerging, pathogens. We welcome reviews and research articles on the evaluation of viral and bacterial vaccines using quantitative antibody assays, functional antibody assays, cellular immunity assays, protective immunity assays, and pathogen neutralizing assays. We also welcome articles introducing new and high-tech assays to replace old methods of vaccine evaluation.

All types of articles, including original research, method articles, reports, and reviews are accepted for publication in this journal to encourage and disseminate your work.

Dr. Ho-Seong Seo
Prof. Joon Young Song
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • vaccine evaluation
  • conjugate vaccine
  • opsonophagocytosis
  • vaccine development
  • viral vaccine
  • cellular immunity
  • toxoid vaccine

Published Papers (9 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review, Other

11 pages, 1371 KiB  
Article
Development and Validation of Enzyme-Linked Immunosorbent Assay for Group B Streptococcal Polysaccharide Vaccine
by A-Yeung Jang, Min-Joo Choi, Yong Zhi, Hyun-Jung Ji, Ji-Yun Noh, Jin-Gu Yoon, Hee-Jin Cheong, Woo-Joo Kim, Ho-Seong Seo and Joon-Young Song
Vaccines 2021, 9(6), 545; https://0-doi-org.brum.beds.ac.uk/10.3390/vaccines9060545 - 21 May 2021
Cited by 2 | Viewed by 2065
Abstract
Streptococcus agalactiae (group B Streptococcus, GBS) is a leading cause of neonatal sepsis and meningitis in infants. Limitations of prenatal GBS screening and intrapartum antibiotic prophylaxis render developing GBS vaccines a high priority. In this study, we developed an enzyme-linked immunosorbent assay [...] Read more.
Streptococcus agalactiae (group B Streptococcus, GBS) is a leading cause of neonatal sepsis and meningitis in infants. Limitations of prenatal GBS screening and intrapartum antibiotic prophylaxis render developing GBS vaccines a high priority. In this study, we developed an enzyme-linked immunosorbent assay (ELISA) for the practical and large-scale evaluation of GBS capsular polysaccharide (PS) vaccine immunogenicity against three main serotypes, Ia, III, and V. GBS-ELISA was developed and subsequently validated using a standardized curve-fitting four-parameter logistic method. Specificity was measured using adsorption of serum with homologous and heterologous PS. Homologous adsorption showed a ≥75% inhibition of all three serotypes, whereas with heterologous PS, IgG GBS-ELISA inhibited only ≤25% of serotypes III and V. However, with serotype Ia, IgG antibody levels decreased by >50%, even after adsorption with heterologous PS (III or V). In comparison, the inhibition opsonophagocytic killing assay (OPA) of serotypes Ia GBS exhibited a reduction in opsonophagocytic activity of only 20% and 1.1% for serotypes III and V GBS, respectively. The precision of the GBS-ELISA was assessed in five independent experiments using four serum samples. The coefficient of variation was <5% for all three serotypes. This standardized GBS-ELISA would be useful for GBS vaccine development and its evaluation. Full article
(This article belongs to the Special Issue Vaccine Evaluation Methods and Studies)
Show Figures

Figure 1

13 pages, 1533 KiB  
Article
Immune Responses to Irradiated Pneumococcal Whole Cell Vaccine
by Eunbyeol Ko, Soyoung Jeong, Min Yong Jwa, A Reum Kim, Ye-Eun Ha, Sun Kyung Kim, Sungho Jeong, Ki Bum Ahn, Ho Seong Seo, Cheol-Heui Yun and Seung Hyun Han
Vaccines 2021, 9(4), 405; https://0-doi-org.brum.beds.ac.uk/10.3390/vaccines9040405 - 19 Apr 2021
Cited by 2 | Viewed by 2357
Abstract
Streptococcus pneumoniae (pneumococcus) can cause respiratory and systemic diseases. Recently, γ-irradiation-inactivated, non-encapsulated, intranasal S. pneumoniae (r-SP) vaccine has been introduced as a novel serotype-independent and cost-effective vaccine. However, the immunogenic mechanism of r-SP is poorly understood. Here, we comparatively investigated the protective immunity [...] Read more.
Streptococcus pneumoniae (pneumococcus) can cause respiratory and systemic diseases. Recently, γ-irradiation-inactivated, non-encapsulated, intranasal S. pneumoniae (r-SP) vaccine has been introduced as a novel serotype-independent and cost-effective vaccine. However, the immunogenic mechanism of r-SP is poorly understood. Here, we comparatively investigated the protective immunity and immunogenicity of r-SP to the heat-(h-SP) or formalin-inactivated vaccine (f-SP) without adjuvants. Mice were intranasally immunized with each vaccine three times and then challenged with a lethal dose of S. pneumoniae TIGR4 strain and then subsequently evaluated for their immune responses. Immunization with r-SP elicited modestly higher protection against S. pneumoniae than h-SP or f-SP. Immunization with r-SP enhanced pneumococcal-specific IgA in the nasal wash and IgG in bronchoalveolar lavage fluid. Immunization with r-SP enhanced S. pneumoniae-specific IgG, IgG1, and IgG2b in the serum. r-SP more potently induced the maturation of dendritic cells in the cervical lymph nodes than h-SP or f-SP. Interestingly, populations of follicular helper T cells and IL-4-producing cells were potently increased in cervical lymph nodes of r-SP-immunized mice. Collectively, r-SP could be an effective intranasal, inactivated whole-cell vaccine in that it elicits S. pneumoniae-specific antibody production and follicular helper T cell activation leading to protective immune responses against S. pneumoniae infection. Full article
(This article belongs to the Special Issue Vaccine Evaluation Methods and Studies)
Show Figures

Figure 1

12 pages, 3252 KiB  
Article
Roles of the Fc Receptor γ-Chain in Inducing Protective Immune Responses after Heterologous Vaccination against Respiratory Syncytial Virus Infection
by Hye Suk Hwang, Young-Tae Lee, Ki-Hye Kim, Ho Seong Seo, Kap Seung Yang, Hoonsung Cho and Sang-Moo Kang
Vaccines 2021, 9(3), 232; https://0-doi-org.brum.beds.ac.uk/10.3390/vaccines9030232 - 08 Mar 2021
Viewed by 2098
Abstract
The roles of the Fc receptor (FcR) in protection or inflammatory disease after respiratory syncytial virus (RSV) vaccination and infection remain unknown. Virus-like particles containing RSV fusion proteins (RSV F-VLPs) induce T-helper type 1 antibody responses and protection against RSV. Heterologous RSV F-VLP [...] Read more.
The roles of the Fc receptor (FcR) in protection or inflammatory disease after respiratory syncytial virus (RSV) vaccination and infection remain unknown. Virus-like particles containing RSV fusion proteins (RSV F-VLPs) induce T-helper type 1 antibody responses and protection against RSV. Heterologous RSV F-VLP prime and formalin-inactivated RSV (FI-RSV) boost vaccination has been reported to be effective in providing protection without inflammatory disease. Here, we investigated whether the FcRγ-chain is important for immune protection by the heterologous F-VLP and FI-RSV vaccination using FcRγ-chain knockout (−/−) mice. RSV F-VLP-primed and FI-RSV-boosted FcRγ −/− mice displayed less protective efficacy, as shown by higher lung viral titers upon RSV challenge, compared to RSV F-VLP-primed and FI-RSV-boosted immunized wild-type mice. RSV F-VLP and FI-RSV immunization induced lower levels of neutralizing activity and interferon-γ-producing CD8 T-cells in the bronchoalveolar lavage cells of FcRγ −/− mice than in those of wild-type mice. In addition, FcRγ −/− mice displayed a trend of enhancing lung histopathology after RSV vaccination and infection. This study suggests that the FcRγ-chain plays an important role in inducing antiviral protection and CD8 T-cell responses in RSV F-VLP prime and FI-RSV boost vaccination after RSV infections. Full article
(This article belongs to the Special Issue Vaccine Evaluation Methods and Studies)
Show Figures

Figure 1

17 pages, 2357 KiB  
Article
Stability of Outer Membrane Vesicles-Based Vaccines, Identifying the Most Appropriate Methods to Detect Changes in Vaccine Potency
by Elena Palmieri, Vanessa Arato, Davide Oldrini, Beatrice Ricchetti, Maria Grazia Aruta, Werner Pansegrau, Sara Marchi, Fabiola Giusti, Ilaria Ferlenghi, Omar Rossi, Renzo Alfini, Carlo Giannelli, Gianmarco Gasperini, Francesca Necchi and Francesca Micoli
Vaccines 2021, 9(3), 229; https://0-doi-org.brum.beds.ac.uk/10.3390/vaccines9030229 - 06 Mar 2021
Cited by 16 | Viewed by 3041
Abstract
Ensuring the stability of vaccines is crucial to successfully performing global immunization programs. Outer Membrane Vesicles (OMV) are receiving great attention as vaccine platforms. OMV are complex molecules and few data have been collected so far on their stability. OMV produced by bacteria, [...] Read more.
Ensuring the stability of vaccines is crucial to successfully performing global immunization programs. Outer Membrane Vesicles (OMV) are receiving great attention as vaccine platforms. OMV are complex molecules and few data have been collected so far on their stability. OMV produced by bacteria, genetically modified to increase their spontaneous release, simplifying their production, are also known as Generalized Modules for Membrane Antigens (GMMA). We have performed accelerated stability studies on GMMA from different pathogens and verified the ability of physico-chemical and immunological methods to detect possible changes. High-temperature conditions (100 °C for 40 min) did not affect GMMA stability and immunogenicity in mice, in contrast to the effect of milder temperatures for a longer period of time (37 °C or 50 °C for 4 weeks). We identified critical quality attributes to monitor during stability assessment that could impact vaccine efficacy. In particular, specific recognition of antigens by monoclonal antibodies through competitive ELISA assays may replace in vivo tests for the potency assessment of GMMA-based vaccines. Full article
(This article belongs to the Special Issue Vaccine Evaluation Methods and Studies)
Show Figures

Figure 1

17 pages, 3701 KiB  
Article
Salmonella Vaccine Vector System for Foot-and-Mouth Disease Virus and Evaluation of Its Efficacy with Virus-Like Particles
by Yong Zhi, Hyun Jung Ji, Huichen Guo, Jae Hyang Lim, Eui-Baek Byun, Woo Sik Kim and Ho Seong Seo
Vaccines 2021, 9(1), 22; https://0-doi-org.brum.beds.ac.uk/10.3390/vaccines9010022 - 05 Jan 2021
Cited by 2 | Viewed by 2863
Abstract
Foot-and-mouth disease virus (FMDV) causes a highly contagious and devastating disease in livestock animals and has a great potential to cause severe economic loss worldwide. The major antigen of FMDV capsid protein, VP1, contains the major B-cell epitope responsible for effectively eliciting protective [...] Read more.
Foot-and-mouth disease virus (FMDV) causes a highly contagious and devastating disease in livestock animals and has a great potential to cause severe economic loss worldwide. The major antigen of FMDV capsid protein, VP1, contains the major B-cell epitope responsible for effectively eliciting protective humoral immunity. In this study, irradiated Salmonella Typhimurium (KST0666) were used as transgenic vectors containing stress-inducible plasmid pRECN-VP1 to deliver the VP1 protein from FMDV-type A/WH/CHA/09. Mice were orally inoculated with ATOMASal-L3 harboring pRECN-VP1, and FMDV virus-like particles, where (VLPFMDV)-specific humoral, mucosal, and cellular immune responses were evaluated. Mice vaccinated with attenuated Salmonella (KST0666) expressing VP1 (named KST0669) showed high levels of VLP-specific IgA in feces and IgG in serum, with high FMDV neutralization titer. Moreover, KST0669-vaccinated mice showed increased population of IFN-γ (type 1 T helper cells; Th1 cells)-, IL-5 (Th2 cells)-, and IL-17A (Th17 cells)-expressing CD4+ as well as activated CD8+ T cells (IFN-γ+CD8+ cells), detected by stimulating VLPFMDV. All data indicate that our Salmonella vector system successfully delivered FMDV VP1 to immune cells and that the humoral and cellular efficacy of the vaccine can be easily evaluated using VLPFMDV in a Biosafety Level I (BSL1) laboratory. Full article
(This article belongs to the Special Issue Vaccine Evaluation Methods and Studies)
Show Figures

Figure 1

10 pages, 621 KiB  
Article
Bacterial Immunogenicity Prediction by Machine Learning Methods
by Ivan Dimitrov, Nevena Zaharieva and Irini Doytchinova
Vaccines 2020, 8(4), 709; https://0-doi-org.brum.beds.ac.uk/10.3390/vaccines8040709 - 30 Nov 2020
Cited by 12 | Viewed by 2855
Abstract
The identification of protective immunogens is the most important and vigorous initial step in the long-lasting and expensive process of vaccine design and development. Machine learning (ML) methods are very effective in data mining and in the analysis of big data such as [...] Read more.
The identification of protective immunogens is the most important and vigorous initial step in the long-lasting and expensive process of vaccine design and development. Machine learning (ML) methods are very effective in data mining and in the analysis of big data such as microbial proteomes. They are able to significantly reduce the experimental work for discovering novel vaccine candidates. Here, we applied six supervised ML methods (partial least squares-based discriminant analysis, k nearest neighbor (kNN), random forest (RF), support vector machine (SVM), random subspace method (RSM), and extreme gradient boosting) on a set of 317 known bacterial immunogens and 317 bacterial non-immunogens and derived models for immunogenicity prediction. The models were validated by internal cross-validation in 10 groups from the training set and by the external test set. All of them showed good predictive ability, but the xgboost model displays the most prominent ability to identify immunogens by recognizing 84% of the known immunogens in the test set. The combined RSM-kNN model was the best in the recognition of non-immunogens, identifying 92% of them in the test set. The three best performing ML models (xgboost, RSM-kNN, and RF) were implemented in the new version of the server VaxiJen, and the prediction of bacterial immunogens is now based on majority voting. Full article
(This article belongs to the Special Issue Vaccine Evaluation Methods and Studies)
Show Figures

Figure 1

14 pages, 11344 KiB  
Article
Comparison of Exosomes Derived from Non- and Gamma-Irradiated Melanoma Cancer Cells as a Potential Antigenic and Immunogenic Source for Dendritic Cell-Based Immunotherapeutic Vaccine
by Woo Sik Kim, DaeSeong Choi, Ji Min Park, Ha-Yeon Song, Ho Seong Seo, Dong-Eun Lee and Eui-Baek Byun
Vaccines 2020, 8(4), 699; https://doi.org/10.3390/vaccines8040699 - 19 Nov 2020
Cited by 18 | Viewed by 2815
Abstract
Cancer cells can secrete exosomes under various stressful conditions, whose functions are involved in the delivery of various biologically active materials into host cells and/or modulation of host immune responses. Therefore, an improved understanding of the immunological interventions that stress-induced tumor exosomes have [...] Read more.
Cancer cells can secrete exosomes under various stressful conditions, whose functions are involved in the delivery of various biologically active materials into host cells and/or modulation of host immune responses. Therefore, an improved understanding of the immunological interventions that stress-induced tumor exosomes have may provide novel therapeutic approaches and more effective vaccine designs. Here, we confirmed the phenotypical and functional alterations of dendritic cells (DCs), which act as a bridge between the innate and adaptive arms of immunity, following non-irradiated (N-exo) and gamma-irradiated melanoma cancer cell-derived exosome (G-exo) stimulation, and evaluated the N-exo- and G-exo-stimulated DCs as therapeutic cancer vaccine candidates. We demonstrated that G-exo-stimulated DCs result in DC maturation by the upregulation of surface molecule expression, pro-inflammatory cytokine release, and antigen-presenting ability, and the downregulation of endocytic capacity. In addition, these cells promoted T cell proliferation and the generation of T helper type 1 (Th1) and interferon (IFN)-γ-producing CD8+ T cells. However, N-exo-stimulated DCs induced semi-mature phenotypes and functions, eventually inhibiting T cell proliferation, decreasing IFN-γ, and increasing IL-10-producing CD4+ T cells. In addition, although N-exo and G-exo stimulations showed similar levels of antigen-specific IFN-γ production, which served as tumor antigen sources in melanoma-specific T cells, G-exo-stimulated DC vaccination conferred a stronger tumor growth inhibition than N-exo-stimulated DC vaccination; further, this was accompanied by a high frequency of tumor-specific, multifunctional effector T cells. These results suggest that gamma irradiation could provide important clues for designing and developing effective exosome vaccines that can induce strong immunogenicity, especially tumor-specific multifunctional T cell responses. Full article
(This article belongs to the Special Issue Vaccine Evaluation Methods and Studies)
Show Figures

Figure 1

Review

Jump to: Research, Other

14 pages, 1890 KiB  
Review
The Immune Correlates of Orthohantavirus Vaccine
by Joon-Yong Bae, Jin Il Kim, Mee Sook Park, Gee Eun Lee, Heedo Park, Ki-Joon Song and Man-Seong Park
Vaccines 2021, 9(5), 518; https://0-doi-org.brum.beds.ac.uk/10.3390/vaccines9050518 - 18 May 2021
Cited by 1 | Viewed by 2508
Abstract
Zoonotic transmission of orthohantaviruses from rodent reservoirs to humans has been the cause of severe fatalities. Human infections are reported worldwide, but vaccines have been approved only in China and Korea. Orthohantavirus vaccine development has been pursued with no sense of urgency due [...] Read more.
Zoonotic transmission of orthohantaviruses from rodent reservoirs to humans has been the cause of severe fatalities. Human infections are reported worldwide, but vaccines have been approved only in China and Korea. Orthohantavirus vaccine development has been pursued with no sense of urgency due to the relative paucity of cases in countries outside China and Korea. However, the orthohantaviruses continuously evolve in hosts and thus the current vaccine may not work as well against some variants. Therefore, a more effective vaccine should be prepared against the orthohantaviruses. In this review, we discuss the issues caused by the orthohantavirus vaccine. Given the pros and cons of the orthohantavirus vaccine, we suggest strategies for the development of better vaccines in terms of pandemic preparedness. Full article
(This article belongs to the Special Issue Vaccine Evaluation Methods and Studies)
Show Figures

Figure 1

Other

Jump to: Research, Review

8 pages, 705 KiB  
Perspective
Evaluating Functional Immunity Following Encapsulated Bacterial Infection and Vaccination
by Zheng Quan Toh, Rachel A. Higgins, Nadia Mazarakis, Elysia Abbott, Jordan Nathanielsz, Anne Balloch, Kim Mulholland and Paul V. Licciardi
Vaccines 2021, 9(6), 677; https://0-doi-org.brum.beds.ac.uk/10.3390/vaccines9060677 - 20 Jun 2021
Cited by 2 | Viewed by 5281
Abstract
Encapsulated bacteria such as Streptococcus pneumoniae, Haemophilus influenzae type b and Neisseria meningitidis cause significant morbidity and mortality in young children despite the availability of vaccines. Highly specific antibodies are the primary mechanism of protection against invasive disease. Robust and standardised assays [...] Read more.
Encapsulated bacteria such as Streptococcus pneumoniae, Haemophilus influenzae type b and Neisseria meningitidis cause significant morbidity and mortality in young children despite the availability of vaccines. Highly specific antibodies are the primary mechanism of protection against invasive disease. Robust and standardised assays that measure functional antibodies are also necessary for vaccine evaluation and allow for the accurate comparison of data between clinical studies. This mini review describes the current state of functional antibody assays and their importance in measuring protective immunity. Full article
(This article belongs to the Special Issue Vaccine Evaluation Methods and Studies)
Show Figures

Figure 1

Back to TopTop